Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy
Advanced Science · 2024
DOI: 10.1002/advs.202309583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yumeng Xing und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei, 230032, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Programs of China, Natural Science Foundation of Anhui Province of China.
Abstract (Originalsprache)
As an essential intracellular immune activation pathway, the cGAS‐STING pathway has attracted broad attention in cancer treatment. However, low bioavailability, nonspecificity, and adverse effects of small molecule STING agonists severely limit their therapeutic efficacy and in vivo application. In this study, a peptide‐based STING agonist is first proposed, and KLA is screened out to activate the cGAS‐STING pathway by promoting mitochondrial DNA (mtDNA) leakage. To precisely activate the cGAS‐STING pathway and block the PD‐1/PD‐L1 pathway, a multi‐stimuli activatable peptide nanodrug (MAPN) is developed for the effective delivery of KLA and PD‐L1 antagonist peptide (CVR). With rational design, MAPN achieved the site‐specific release of KLA and CVR in response to multiple endogenous stimuli, simultaneously activating the cGAS‐STING pathway and blocking PD‐1/PD‐L1 pathway, ultimately initiating robust and durable T cell anti‐tumor immunity with a tumor growth inhibition rate of 78% and extending the median survival time of B16F10 tumor‐bearing mice to 40 days. Overall, antimicrobial peptides, which can promote mtDNA leakage through damaging mitochondrial membranes, may be potential alternatives for small molecule STING agonists and giving a new insight for the design of novel STING agonists. Furthermore, MAPN presents a universal delivery platform for the effective synergy of multiple peptides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui Medical University, Hefei, 230032, China.
- College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China.
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.
- College of Chemistry, Nankai University, Tianjin, 300071, China.
ORCID-Profile: Qi Liu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Programs of China
- Natural Science Foundation of Anhui Province of China
- Natural Science Research Project for Anhui Universities
- Open Project of Key Laboratory of Functional Polymer
- Ministry of Education
- Kementerian Pendidikan
Zitieren
APA
Xing, Y., Peng, A., Yang, J., Cheng, Z., Yue, Y., Liu, F., Li, F., Liu, Y., & Liu, Q. (2024). Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202309583
Vancouver
Xing Y, Peng A, Yang J, Cheng Z, Yue Y, Liu F, et al. Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy. Advanced Science. 2024. doi:10.1002/advs.202309583
BibTeX
@article{Xing2024,
author = {Xing, Yumeng and Peng, Ao and Yang, Jianhui and Cheng, Zhifei and Yue, Yi and Liu, Feilong and Li, Fenghe and Liu, Yang and Liu, Qi},
title = {Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202309583}
}
EUVIMED